Thursday - April 23, 2026

Category Archives: Business

Laser Welding Machine Market on Track to More than Double by 2033, Fuelled by Electric Vehicle Surge and Precision Manufacturing Demand

Laser Welding Machine Market From battery assembly lines to aerospace fabrication, laser welding technology is becoming an indispensable pillar of modern industrial production — and the growth numbers reflect it. The Global Laser Welding Machine Industry is undergoing one of … Continue reading →

Idiopathic Pulmonary Fibrosis Pipeline Progresses as 80+ Pharma Companies Advance Novel Lung Disease Therapies, Finds DelveInsight | Bristol-Myers Squibb, Genentech, Tvardi Therapeutics, Melius Pharma

Idiopathic Pulmonary Fibrosis Pipeline Insight There are 80+ key companies, including Bristol-Myers Squibb, Genentech, Tvardi Therapeutics, Melius Pharma, Resproly, and others, developing therapies for Idiopathic Pulmonary Fibrosis, with Bristol-Myers Squibb having its IPF drug candidate in the most advanced Phase … Continue reading →

B-cell Lymphoma Pipeline Grows as 295+ Pharma Companies Advance Novel Lymphoma Therapies, Finds DelveInsight | Bristol Myers Squibb, Roche, Nektar Therapeutics, Miltenyi Biotec

B-cell Lymphoma Pipeline Insight There are 295+ key companies, including Bristol Myers Squibb, Roche, Nektar Therapeutics, Miltenyi Biotec, and others, developing therapies for B-cell Lymphoma, with several candidates such as Lisocabtagene maraleucel in the advanced Phase III stage. DelveInsight’s “B-cell … Continue reading →

Liver Cancer Pipeline Grows as 70+ Pharma Companies Advance Novel Liver Cancer Therapies, Finds DelveInsight | Can-Fite BioPharma, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche

Liver Cancer Pipeline Insight There are 70+ key companies, including Can-Fite BioPharma, Yiviva, Tvardi Therapeutics, Biosion, Novartis, Roche, and others, developing therapies for Liver Cancer, with Can-Fite BioPharma having its Liver Cancer drug candidate in the most advanced Phase III … Continue reading →

Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin

Antisense Oligonucleotide Therapeutics Pipeline Insights The Antisense Oligonucleotide landscape features 70+ key companies, including Novartis, Wave Life Sciences, Bio-Path Holdings, and others, advancing over 90 pipeline drugs. Companies like Novartis and Wave Life Sciences are currently leading with candidates in … Continue reading →

Global Ophthalmic Devices Market Set to Surpass USD 44 Billion by 2032, Driven by Rising Vision Disorders, AI Integration, and Expanding Geriatric Population | DelveInsight

Ophthalmic Devices Market The global ophthalmic devices market is entering a transformative growth phase, fueled by a surge in eye-related disorders, rapid technological innovation, and increasing global awareness around vision care. According to DelveInsight’s latest market intelligence report, the ophthalmic … Continue reading →

Non-Alcoholic Fatty Liver Disease Pipeline Shows Strong Momentum as 90+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Non-Alcoholic Fatty Liver Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the Non Alcoholic Fatty Liver Disease pipeline drug profiles, including clinical and … Continue reading →

Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Marginal Zone Lymphoma Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and … Continue reading →